Clinical Trial VICCTHNP1353

Title

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)

Principal Investigator(s)

Leora Horn

Details

  • Protocol No. VICCTHNP1353
  • Open Date: 10/30/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To investigate the safety and tolerability of AZD9291 when given orally to patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have progressed following prior therapy with an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) agent.
  • Disease Sites: Lung
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: AZD9291
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01802632
  • Secondary Protocol No: D5160C00001

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.